IDEXX Integrates SDMA Biomarker into Catalyst for Enhanced Kidney Function Evaluation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 19 2026
0mins
Source: Newsfilter
- Kidney Function Evaluation Upgrade: IDEXX announced the integration of the SDMA biomarker into Catalyst™ CLIPs, making kidney function evaluation part of the most common point-of-care chemistry profiles, with availability starting in June in the U.S. and Canada, significantly enhancing veterinarians' ability to identify kidney function loss earlier.
- Clinical Importance Enhancement: Since the introduction of the IDEXX SDMA™ Test in 2015, approximately 119 million SDMA patient tests have been conducted globally, underscoring the test's broad adoption and clinical significance in kidney health evaluation, further solidifying IDEXX's leadership in the pet healthcare sector.
- Early Intervention Potential: Studies indicate that including SDMA in routine testing enables earlier detection of significant declines in kidney function, allowing veterinarians to take action sooner, thereby improving health outcomes for pets and enhancing the long-term growth potential of veterinary practices.
- Market Demand Response: IDEXX CEO Mike Erickson emphasized that the integration of SDMA not only improves workflow efficiency for veterinarians but also meets the urgent market demand for early kidney disease assessment by providing more clinically relevant diagnostic tools, further driving the company's strategic development in pet healthcare innovation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IDXX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IDXX
Wall Street analysts forecast IDXX stock price to rise
10 Analyst Rating
7 Buy
3 Hold
0 Sell
Moderate Buy
Current: 568.030
Low
750.00
Averages
792.78
High
850.00
Current: 568.030
Low
750.00
Averages
792.78
High
850.00
About IDXX
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and provides services primarily for the companion animal veterinary; livestock, poultry and dairy; and water testing industries. It also manufactures and sells human medical point-of-care diagnostic products. Its products and services include point-of-care veterinary diagnostic products, comprised of instruments, consumables, and rapid assay test kits. It also includes veterinary reference laboratory diagnostic and consulting services. It offers practice management systems, software and diagnostic imaging systems and services used by veterinarians. It also offers health monitoring, biological materials testing, laboratory diagnostic instruments, and services used by the biomedical research community. The Company provides diagnostic and health-monitoring products for livestock, poultry, and dairy; and products that test water for certain microbiological contaminants.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IDEXX Integrates Kidney Disease Detector into Popular Test Profiles
- Technology Integration: IDEXX announced the integration of the SDMA kidney biomarker into its most popular Catalyst CLIPs tests, set to roll out next month in the U.S. and Canada, enhancing diagnostic efficiency for veterinarians.
- Early Detection Advantage: SDMA can detect kidney function decline at 25-40%, while traditional creatinine markers often only show issues at 75% decline, significantly increasing the potential for early intervention.
- Cost Efficiency Improvement: The new system embeds SDMA data within Chem 11, Chem 16, and Chem 18 Catalyst CLIPs tests at no additional cost, streamlining testing processes for veterinarians and improving customer satisfaction.
- Strategic Expansion: IDEXX CEO Mike Erickson emphasized that this move is part of the company's scaling strategy, further solidifying its leadership in the veterinary diagnostics market by integrating innovative diagnostic tools into existing platforms.
See More
IDEXX Integrates SDMA Biomarker into Catalyst for Enhanced Kidney Function Evaluation
- Kidney Function Evaluation Upgrade: IDEXX announced the integration of the SDMA biomarker into Catalyst™ CLIPs, making kidney function evaluation part of the most common point-of-care chemistry profiles, with availability starting in June in the U.S. and Canada, significantly enhancing veterinarians' ability to identify kidney function loss earlier.
- Clinical Importance Enhancement: Since the introduction of the IDEXX SDMA™ Test in 2015, approximately 119 million SDMA patient tests have been conducted globally, underscoring the test's broad adoption and clinical significance in kidney health evaluation, further solidifying IDEXX's leadership in the pet healthcare sector.
- Early Intervention Potential: Studies indicate that including SDMA in routine testing enables earlier detection of significant declines in kidney function, allowing veterinarians to take action sooner, thereby improving health outcomes for pets and enhancing the long-term growth potential of veterinary practices.
- Market Demand Response: IDEXX CEO Mike Erickson emphasized that the integration of SDMA not only improves workflow efficiency for veterinarians but also meets the urgent market demand for early kidney disease assessment by providing more clinically relevant diagnostic tools, further driving the company's strategic development in pet healthcare innovation.
See More
MindWalk Reports Significant Progress in Drug Development
- Clinical Trial Count: MindWalk's antibody discovery efforts have led to over 20 partner-owned drug programs entering clinical trials, with ten currently in active Phase 1-3 trials, showcasing the company's robust R&D capabilities in biopharmaceuticals.
- Establishing Scientific Standards: With over 400 peer-reviewed publications and patents, MindWalk has established a rare scientific standard in the industry, ensuring a consistent output of clinical-stage assets across multiple therapeutic areas for its partners.
- Biological Intelligence Infrastructure: The HYFT® system and LensAI™ platform, developed as a purpose-built AI architecture, integrate biological pattern recognition technology, enhancing the efficiency and success rate of clinical asset development within MindWalk's antibody discovery engine.
- Strategic Partnerships: MindWalk collaborates with several prominent biopharmaceutical companies, including Annexon Biosciences and argenx, further solidifying its market position and influence in the biopharmaceutical industry.
See More
IDEXX Announces 2026 Investor Day and Conference Participation
- Executive Conference Participation: IDEXX's CEO Mike Erickson will participate in the Stifel Jaws & Paws Conference on May 27, 2026, showcasing the company's leadership in pet healthcare innovation, which is expected to attract investor interest and enhance the company's image.
- Investor Day Announcement: IDEXX will host its 2026 Investor Day on August 13, 2026, at its headquarters in Maine, which is anticipated to strengthen relationships with institutional investors and provide in-depth insights into the company's future strategies.
- Live Webcast Support: The live audio webcasts for both the conference and Investor Day will be available through IDEXX's website, ensuring global investors can access real-time information, thereby enhancing transparency and investor confidence.
- Global Impact: IDEXX operates in over 175 countries with approximately 11,000 employees, continuously driving innovation in pet healthcare and public health, further solidifying its position within the S&P 500 Index.
See More
IDEXX Laboratories Q1 2026 Earnings Call Highlights
- Significant Revenue Growth: IDEXX reported a 14% year-over-year revenue increase and an 11% organic growth in Q1 2026, with earnings per share at $3.47, reflecting the company's strong performance driven by innovation and a global customer base.
- Strong Instrument Sales: CAG instrument revenues saw a 28% organic growth, primarily due to the strong sales of 1,100 IDEXX inVue Dx analyzers, indicating the company's increasing competitiveness in the high-end diagnostic equipment market.
- International Market Expansion: The successful launch of Cancer Dx for canine lymphoma in Europe and Australia, with nearly 70% of tests run as part of a panel in North America, marks IDEXX's further penetration into global markets.
- Optimistic Future Outlook: IDEXX raised its full-year revenue guidance for 2026 to between $4.675 billion and $4.760 billion, with expected earnings per share between $14.45 and $14.90, demonstrating management's confidence in future performance.
See More
IDEXX Laboratories Q1 Earnings Beat Expectations
- Earnings Beat: IDEXX reported Q1 GAAP EPS of $3.47, exceeding expectations by $0.06, indicating sustained profitability and competitive strength in the market.
- Significant Revenue Growth: The company achieved revenue of $1.14 billion, a 14.2% year-over-year increase, surpassing market expectations by $30 million, demonstrating strong product demand, particularly in the CAG Diagnostics segment.
- 2026 Revenue Guidance Raised: IDEXX increased its 2026 revenue guidance to $4.675 billion to $4.76 billion, exceeding market consensus by $420 million, with expectations that CAG Diagnostics will drive continued growth, boosting investor confidence.
- EPS Outlook Upgraded: The company raised its 2026 EPS outlook to $14.45 to $14.90, reflecting a $0.13 increase from prior guidance midpoint, supported by optimistic expectations for revenue growth and comparable operating margin expansion.
See More
IDEXX Integrates Kidney Disease Detector into Popular Test Profiles
- Technology Integration: IDEXX announced the integration of the SDMA kidney biomarker into its most popular Catalyst CLIPs tests, set to roll out next month in the U.S. and Canada, enhancing diagnostic efficiency for veterinarians.
- Early Detection Advantage: SDMA can detect kidney function decline at 25-40%, while traditional creatinine markers often only show issues at 75% decline, significantly increasing the potential for early intervention.
- Cost Efficiency Improvement: The new system embeds SDMA data within Chem 11, Chem 16, and Chem 18 Catalyst CLIPs tests at no additional cost, streamlining testing processes for veterinarians and improving customer satisfaction.
- Strategic Expansion: IDEXX CEO Mike Erickson emphasized that this move is part of the company's scaling strategy, further solidifying its leadership in the veterinary diagnostics market by integrating innovative diagnostic tools into existing platforms.
See More
IDEXX Integrates SDMA Biomarker into Catalyst for Enhanced Kidney Function Evaluation
- Kidney Function Evaluation Upgrade: IDEXX announced the integration of the SDMA biomarker into Catalyst™ CLIPs, making kidney function evaluation part of the most common point-of-care chemistry profiles, with availability starting in June in the U.S. and Canada, significantly enhancing veterinarians' ability to identify kidney function loss earlier.
- Clinical Importance Enhancement: Since the introduction of the IDEXX SDMA™ Test in 2015, approximately 119 million SDMA patient tests have been conducted globally, underscoring the test's broad adoption and clinical significance in kidney health evaluation, further solidifying IDEXX's leadership in the pet healthcare sector.
- Early Intervention Potential: Studies indicate that including SDMA in routine testing enables earlier detection of significant declines in kidney function, allowing veterinarians to take action sooner, thereby improving health outcomes for pets and enhancing the long-term growth potential of veterinary practices.
- Market Demand Response: IDEXX CEO Mike Erickson emphasized that the integration of SDMA not only improves workflow efficiency for veterinarians but also meets the urgent market demand for early kidney disease assessment by providing more clinically relevant diagnostic tools, further driving the company's strategic development in pet healthcare innovation.
See More
MindWalk Reports Significant Progress in Drug Development
- Clinical Trial Count: MindWalk's antibody discovery efforts have led to over 20 partner-owned drug programs entering clinical trials, with ten currently in active Phase 1-3 trials, showcasing the company's robust R&D capabilities in biopharmaceuticals.
- Establishing Scientific Standards: With over 400 peer-reviewed publications and patents, MindWalk has established a rare scientific standard in the industry, ensuring a consistent output of clinical-stage assets across multiple therapeutic areas for its partners.
- Biological Intelligence Infrastructure: The HYFT® system and LensAI™ platform, developed as a purpose-built AI architecture, integrate biological pattern recognition technology, enhancing the efficiency and success rate of clinical asset development within MindWalk's antibody discovery engine.
- Strategic Partnerships: MindWalk collaborates with several prominent biopharmaceutical companies, including Annexon Biosciences and argenx, further solidifying its market position and influence in the biopharmaceutical industry.
See More
IDEXX Announces 2026 Investor Day and Conference Participation
- Executive Conference Participation: IDEXX's CEO Mike Erickson will participate in the Stifel Jaws & Paws Conference on May 27, 2026, showcasing the company's leadership in pet healthcare innovation, which is expected to attract investor interest and enhance the company's image.
- Investor Day Announcement: IDEXX will host its 2026 Investor Day on August 13, 2026, at its headquarters in Maine, which is anticipated to strengthen relationships with institutional investors and provide in-depth insights into the company's future strategies.
- Live Webcast Support: The live audio webcasts for both the conference and Investor Day will be available through IDEXX's website, ensuring global investors can access real-time information, thereby enhancing transparency and investor confidence.
- Global Impact: IDEXX operates in over 175 countries with approximately 11,000 employees, continuously driving innovation in pet healthcare and public health, further solidifying its position within the S&P 500 Index.
See More
IDEXX Laboratories Q1 2026 Earnings Call Highlights
- Significant Revenue Growth: IDEXX reported a 14% year-over-year revenue increase and an 11% organic growth in Q1 2026, with earnings per share at $3.47, reflecting the company's strong performance driven by innovation and a global customer base.
- Strong Instrument Sales: CAG instrument revenues saw a 28% organic growth, primarily due to the strong sales of 1,100 IDEXX inVue Dx analyzers, indicating the company's increasing competitiveness in the high-end diagnostic equipment market.
- International Market Expansion: The successful launch of Cancer Dx for canine lymphoma in Europe and Australia, with nearly 70% of tests run as part of a panel in North America, marks IDEXX's further penetration into global markets.
- Optimistic Future Outlook: IDEXX raised its full-year revenue guidance for 2026 to between $4.675 billion and $4.760 billion, with expected earnings per share between $14.45 and $14.90, demonstrating management's confidence in future performance.
See More
IDEXX Laboratories Q1 Earnings Beat Expectations
- Earnings Beat: IDEXX reported Q1 GAAP EPS of $3.47, exceeding expectations by $0.06, indicating sustained profitability and competitive strength in the market.
- Significant Revenue Growth: The company achieved revenue of $1.14 billion, a 14.2% year-over-year increase, surpassing market expectations by $30 million, demonstrating strong product demand, particularly in the CAG Diagnostics segment.
- 2026 Revenue Guidance Raised: IDEXX increased its 2026 revenue guidance to $4.675 billion to $4.76 billion, exceeding market consensus by $420 million, with expectations that CAG Diagnostics will drive continued growth, boosting investor confidence.
- EPS Outlook Upgraded: The company raised its 2026 EPS outlook to $14.45 to $14.90, reflecting a $0.13 increase from prior guidance midpoint, supported by optimistic expectations for revenue growth and comparable operating margin expansion.
See More
